Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise
In the second quarter of 2026, Merck & Co., Inc., a prominent healthcare company, achieved a market capitalization of $357.52 billion, with its shares trading between $77.58 and $156.92 over the past year. The company reported a 2.74% decline in stock price on September 16, 2026, but demonstrated resilience with a 52-week gain of 77.74%.
Merck has been diversifying its revenue streams away from its primary cancer drug Keytruda, successfully launching new products such as Winrevair, Welireg, and Capvaxive. Despite being absent from the list of the 40 most popular stocks among hedge funds, Merck & Co., Inc. (NYSE:MRK) was held by 101 portfolios at the end of Q2 2026, similar to the previous quarter.
The investment advisory firm Auxier Asset Management acknowledged the potential of Merck as an investment but expressed the belief that certain AI stocks offer greater upside potential and lower risk.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
